Fidelity SPDR Advertisement
Home > Boards > Free Zone > Health and Sciences > Biotech Values

VVUS—This might be a good time to review

Public Reply | Private Reply | Keep | Last ReadPost New MsgReplies (1) | Next 10 | Previous | Next
DewDiligence Member Profile
Member Level 
Followed By 489
Posts 82,150
Boards Moderated 24
Alias Born 09/05/02
160x600 placeholder
Novartis says an important new drug for treating heart failure has been granted an accelerated review by European authorities, improving its chances of approval in Europe next year.
More Top Equities Stories Of The Day
Taiwan Predicts Steady Growth Next Year
Telefónica Works to Redraw Its Empire
Canada Resident Caught Up in China Corruption Probe
Hutchison Whampoa Prepping Bid for U.K.'s EE or O2 -Reuters
Correction to La Compagnie Fares Story
SEC Grants Bank of America Short-Term Waiver from Hedge-Fund Restrictions
Deere Projects Sharp Decline in Farm-Equipment Sales -- 2nd Update
U.S. Stocks Close Higher
DewDiligence Member Level  Thursday, 02/23/12 11:29:54 AM
Re: biotech jim post# 137678
Post # of 184218 
VVUS—This might be a good time to review the table in #msg-59407483 :- )

Note that Contrave is one of the items on the list.

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”
Public Reply | Private Reply | Keep | Last ReadPost New MsgReplies (1) | Next 10 | Previous | Next
Follow Board Follow Board Keyboard Shortcuts Report TOS Violation
X
Current Price
Change
Volume
Detailed Quote - Discussion Board
Intraday Chart
+/- to Watchlist